Publikationen in Zusammenarbeit mit Forschern von Universidad de Salamanca (12)

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

2020

  1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

2018

  1. Cancertool: A visualization and representation interface to exploit cancer datasets

    Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328

2016

  1. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    Journal of Pathology, Vol. 239, Núm. 4, pp. 438-449

2014

  1. A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer

    Oncogene, Vol. 33, Núm. 43, pp. 5090-5099

  2. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner

    Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206

2008

  1. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism

    Cancer Research, Vol. 68, Núm. 7, pp. 2275-2285

2007

  1. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model

    Journal of Molecular Medicine, Vol. 85, Núm. 9, pp. 1015-1029